ArticleFrontiers in endocrinology2026
Estrogen signaling processes in fibroblasts: a scoping review.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Melasma: When Dermal Photoageing Precedes Melanocyte Ageing.Experimental dermatology · 2026Review
- Microbiome-Directed Bioactive Strategies in Skin Aging: Mechanistic Insights and Precision Nanocarrier Delivery Approaches.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblasts are a heterogeneous cell population with distinct functions, known to respond to estrogens through nuclear estrogen receptor alpha and beta (ERα, ERβ), and the membrane G protein-coupled estrogen receptor (GPER). In this scoping review, we systematically mapped the current evidence on the contribution of estrogen, phytoestrogens, and selective estrogen receptor modulators (SERMs) on estrogen signaling in fibroblasts. A systematic search across PubMed, Scopus and EMBASE was conducted, followed by screening of titles/abstracts, and full text in Covidence, resulting in 67 eligible studies. Our findings reveal that fibroblasts respond to estradiol (E2), phytoestrogens, and SERMs, activating both genomic and non-genomic responses through ERα, ERβ and GPER. These responses contribute to anti-fibrosis, wound healing, anti-inflammatory, and protective effects across diverse fibroblast models. In contrast, in cancer-associated fibroblasts, these ligands can promote cancer in a paracrine manner, emphasizing the role of the tumor microenvironment in cancer progression. However, significant gaps including small sample sizes, high ligand concentrations, lack of mechanistic detail and limited investigation of sex-specific fibroblast responses remain. Addressing these gaps by standardized experimental designs, physiologically relevant models, clearer distinction of receptor-specific pathways and sex-specific analyses in future research will advance the understanding of estrogen-mediated fibroblast signaling and aid in the development of novel therapeutic targets for estrogen-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.